Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge.
A case of neuroleptic malignant syndrome (NMS) in a patient with Parkinson's disease (PD) is presented. The syndrome was precipitated by the atypical antipsychotic, ziprasidone. The challenge of recognizing NMS in a patient with underlying parkinsonian symptoms, where prominent symptom overlap can occur, is discussed.
Gray
Nicola S
NS
Department of Psychiatry, Allegheny General Hospital, Four Allegheny Center, 8th Floor, Pittsburgh, PA 15212-4772, USA. nsgstl@hotmail.com
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D010300:Parkinson Disease / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone